NCT07041762 Rhomboid Intercostal Block With Sub-Serratus Plane Block Versus Erector Spinae Block
| NCT ID | NCT07041762 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Breast Cancer Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-06-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study compares two nerve block techniques-Rhomboid Intercostal with Sub-Serratus Plane Block versus Erector Spinae Plane Block-for pain relief after breast cancer surgery. It aims to determine which method provides better postoperative pain control, reduces opioid use, and improves recovery in patients undergoing modified radical mastectomy at the National Cancer Institute, Cairo University.
Eligibility Criteria
Inclusion Criteria: * Female breast cancer patients undergoing Modified Radical Mastectomy (MRM) ASA physical status II or III Age between 18 and 65 years Body Mass Index (BMI) \> 20 kg/m² and \< 35 kg/m² Exclusion Criteria: * Patient refusal ASA physical status IV Age \<18 years or \>65 years BMI \< 20 kg/m² or \> 35 kg/m² Known allergy or contraindication to local anesthetics or opioids History of psychological disorders or chronic pain Contraindications to regional anesthesia (e.g., coagulopathy, local infection, peripheral neuropathy) Severe respiratory, cardiac, hepatic, or renal disease
Contact & Investigator
Sayed Mahmoud M Abed, MD
PRINCIPAL INVESTIGATOR
National Cancer Institute - Cairo University
Frequently Asked Questions
Who can join the NCT07041762 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Breast Cancer Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07041762 currently recruiting?
Yes, NCT07041762 is actively recruiting participants. Contact the research team at sayed.abed@nci.cu.edu.eg for enrollment information.
Where is the NCT07041762 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07041762 clinical trial?
NCT07041762 is sponsored by Cairo University. The principal investigator is Sayed Mahmoud M Abed, MD at National Cancer Institute - Cairo University. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.